Krishna Nalleballe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Krishna Nalleballe has a total of 921 co-authors. Here are the top co-authors by number of shared publications:
Sanjeeva Onteddu
University of Arkansas for Medical Sciences
21 shared publications- Sanjeeva Onteddu
Department of Neurology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
17 shared publications Rohan Sharma
Department of Neurology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
12 shared publicationsNidhi Kapoor
Department of Neurology University of Arkansas for Medical Sciences Little Rock Arkansas USA
11 shared publications- Sen Sheng
Neurology, University of Arkansas for Medical Sciences, Little Rock, USA
11 shared publications Aliza Brown
Department of Neurology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
10 shared publications
Latest Publications
- Open Access
- 19 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (16) , e042767
Bleeding Risk With Combining Antiplatelets and Anticoagulants for Secondary Stroke Prevention: A Propensity Score–Matched Analysis
Background: Limited data exist on the safety of combining antiplatelets and anticoagulants for secondary stroke prevention in acute ischemic stroke (AIS). We sought to examine the hemorrhage risk with combining single (SAPT) or dual antiplatelet therapy (DAPT) with anticoagulants in patients with AIS with concomitant atrial fibrillation and acute myocardial infarction. Methods: This retrospective cross‐sectional cohort study used TriNetX to collect data from 76 hospitals in the United States. Adult patients with diagnoses of AIS, atrial fibrillation, and acute myocardial infarction were identified using International Classification of Diseases , Tenth Revision ( ICD‐10 ) codes. Propensity score–matched analysis, compared the odds for acute spontaneous intracerebral hemorrhage and gastrointestinal bleeding at 3 months, 12 months, and throughout follow‐up within TriNetX, among 3 matched subcohorts: anticoagulant alone, anticoagulant plus SAPT, and anticoagulant plus DAPT. Results: Among 144 434 patients with AIS, atrial fibrillation, and myocardial infarction (mean age, 71.9 years; 43.3% women), 8772 (6.1%) patients received anticoagulants alone, 88 430 (61.2%) received anticoagulant plus SAPT, and 47 232 (32.7%) received anticoagulants plus DAPT. After propensity score matching, 8706 patients were included in each subcohort. Compared with anticoagulant alone, anticoagulant plus SAPT and anticoagulant plus DAPT showed no significant increase in intracerebral hemorrhage risk at 3 and 12 months but increased long‐term risk (odds ratio for anticoagulant plus SAPT, 1.26 [95% CI, 1.11–1.44], P P <0.001). Gastrointestinal bleeding risk was elevated at all time points with combination therapies. Conclusions: Combining antiplatelets with anticoagulants after AIS may be associated an increased risk of intracerebral hemorrhage in the long term, particularly beyond 12 months, but with an increased risk of acute gastrointestinal bleeding in the short and long term. Larger prospective studies are warranted to confirm our findings.
- 19 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (16) , e042767
Open AccessBleeding Risk With Combining Antiplatelets and Anticoagulants for Secondary Stroke Prevention: A Propensity Score–Matched Analysis
Background: Limited data exist on the safety of combining antiplatelets and anticoagulants for secondary stroke prevention in acute ischemic stroke (AIS). We sought to examine the hemorrhage risk with combining single (SAPT) or dual antiplatelet therapy (DAPT) with anticoagulants in patients with AIS with concomitant atrial fibrillation and acute myocardial infarction. Methods: This retrospective cross‐sectional cohort study used TriNetX to collect data from 76 hospitals in the United States. Adult patients with diagnoses of AIS, atrial fibrillation, and acute myocardial infarction were identified using International Classification of Diseases , Tenth Revision ( ICD‐10 ) codes. Propensity score–matched analysis, compared the odds for acute spontaneous intracerebral hemorrhage and gastrointestinal bleeding at 3 months, 12 months, and throughout follow‐up within TriNetX, among 3 matched subcohorts: anticoagulant alone, anticoagulant plus SAPT, and anticoagulant plus DAPT. Results: Among 144 434 patients with AIS, atrial fibrillation, and myocardial infarction (mean age, 71.9 years; 43.3% women), 8772 (6.1%) patients received anticoagulants alone, 88 430 (61.2%) received anticoagulant plus SAPT, and 47 232 (32.7%) received anticoagulants plus DAPT. After propensity score matching, 8706 patients were included in each subcohort. Compared with anticoagulant alone, anticoagulant plus SAPT and anticoagulant plus DAPT showed no significant increase in intracerebral hemorrhage risk at 3 and 12 months but increased long‐term risk (odds ratio for anticoagulant plus SAPT, 1.26 [95% CI, 1.11–1.44], P P <0.001). Gastrointestinal bleeding risk was elevated at all time points with combination therapies. Conclusions: Combining antiplatelets with anticoagulants after AIS may be associated an increased risk of intracerebral hemorrhage in the long term, particularly beyond 12 months, but with an increased risk of acute gastrointestinal bleeding in the short and long term. Larger prospective studies are warranted to confirm our findings.
- Open Access
Bleeding Risk with Combination Antithrombotic Therapy: A Propensity-Score Matched Analysis
Background: Limited data exist on the safety of combining antiplatelets and anticoagulants (AC) for secondary stroke prevention in acute ischemic stroke (AIS). We sought to examine the hemorrhage risk with combining single (SAPT) or dual antiplatelet therapy (DAPT) with AC in AIS patients with concomitant atrial fibrillation (AF) and acute myocardial infarction (MI). Methods: This retrospective cross-sectional cohort study used TriNetX, a federated health analytics database that collects real-time electronic health records data from 76 participating healthcare organizations in the United States. Through queries performed on March 31, 2023, adult patients with simultaneous diagnoses of AIS, AF and acute MI were identified using ICD-10 codes over the past 20 years. Propensity score-matched analysis, matching for demographics and vascular co-morbidities, compared the odds for acute spontaneous ICH and GI bleeding at 3-months, 12-months and throughout follow-up within TriNetX, between three matched sub-cohorts: AC alone, AC+SAPT, and AC+DAPT. Results: Among 144,434 AIS patients with AF and MI (mean age, 71.9 years; 43.3% female), 8772 (6.1%) patients received AC alone, 88,430 (61.2%) received AC+SAPT, and 47,232 (32.7%) received AC+DAPT. After propensity-score matching, 8,706 patients were included in each sub-cohort. Compared to AC alone, AC+SAPT and AC+DAPT showed no significant increase in ICH risk at 3 and 12 months but increased long-term risk throughout follow-up (odds ratio [95% confidence intervals] for AC+SAPT, 1.26 [1.11-1.44], pp <0.001). Gastrointestinal (GI) bleeding risk was elevated at all time-points with combination therapies. Conclusion: Within the limitations of a retrospective cross-sectional study using administrative data, this large propensity-score matched analysis demonstrates that combining antiplatelets with anticoagulants after AIS may be associated an increased risk of ICH only in the long-term, beyond 12-months, but with an increased risk of acute GI bleeding in the short and long-term. Larger prospective studies are warranted to confirm our findings.
Open AccessBleeding Risk with Combination Antithrombotic Therapy: A Propensity-Score Matched Analysis
Background: Limited data exist on the safety of combining antiplatelets and anticoagulants (AC) for secondary stroke prevention in acute ischemic stroke (AIS). We sought to examine the hemorrhage risk with combining single (SAPT) or dual antiplatelet therapy (DAPT) with AC in AIS patients with concomitant atrial fibrillation (AF) and acute myocardial infarction (MI). Methods: This retrospective cross-sectional cohort study used TriNetX, a federated health analytics database that collects real-time electronic health records data from 76 participating healthcare organizations in the United States. Through queries performed on March 31, 2023, adult patients with simultaneous diagnoses of AIS, AF and acute MI were identified using ICD-10 codes over the past 20 years. Propensity score-matched analysis, matching for demographics and vascular co-morbidities, compared the odds for acute spontaneous ICH and GI bleeding at 3-months, 12-months and throughout follow-up within TriNetX, between three matched sub-cohorts: AC alone, AC+SAPT, and AC+DAPT. Results: Among 144,434 AIS patients with AF and MI (mean age, 71.9 years; 43.3% female), 8772 (6.1%) patients received AC alone, 88,430 (61.2%) received AC+SAPT, and 47,232 (32.7%) received AC+DAPT. After propensity-score matching, 8,706 patients were included in each sub-cohort. Compared to AC alone, AC+SAPT and AC+DAPT showed no significant increase in ICH risk at 3 and 12 months but increased long-term risk throughout follow-up (odds ratio [95% confidence intervals] for AC+SAPT, 1.26 [1.11-1.44], pp <0.001). Gastrointestinal (GI) bleeding risk was elevated at all time-points with combination therapies. Conclusion: Within the limitations of a retrospective cross-sectional study using administrative data, this large propensity-score matched analysis demonstrates that combining antiplatelets with anticoagulants after AIS may be associated an increased risk of ICH only in the long-term, beyond 12-months, but with an increased risk of acute GI bleeding in the short and long-term. Larger prospective studies are warranted to confirm our findings.
- 24 January 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (4) , e408-e421
Global Impact of the COVID-19 Pandemic on Stroke Volumes and Cerebrovascular Events
Background and Objectives Declines in stroke admission, IV thrombolysis (IVT), and mechanical thrombectomy volumes were reported during the first wave of the COVID-19 pandemic. There is a paucity of data on the longer-term effect of the pandemic on stroke volumes over the course of a year and through the second wave of the pandemic. We sought to measure the effect of the COVID-19 pandemic on the volumes of stroke admissions, intracranial hemorrhage (ICH), IVT, and mechanical thrombectomy over a 1-year period at the onset of the pandemic (March 1, 2020, to February 28, 2021) compared with the immediately preceding year (March 1, 2019, to February 29, 2020). Methods We conducted a longitudinal retrospective study across 6 continents, 56 countries, and 275 stroke centers. We collected volume data for COVID-19 admissions and 4 stroke metrics: ischemic stroke admissions, ICH admissions, IVT treatments, and mechanical thrombectomy procedures. Diagnoses were identified by their ICD-10 codes or classifications in stroke databases. Results There were 148,895 stroke admissions in the 1 year immediately before compared with 138,453 admissions during the 1-year pandemic, representing a 7% decline (95% CI [95% CI 7.1–6.9]; p < 0.0001). ICH volumes declined from 29,585 to 28,156 (4.8% [5.1–4.6]; p < 0.0001) and IVT volume from 24,584 to 23,077 (6.1% [6.4–5.8]; p < 0.0001). Larger declines were observed at high-volume compared with low-volume centers (all p < 0.0001). There was no significant change in mechanical thrombectomy volumes (0.7% [0.6–0.9]; p = 0.49). Stroke was diagnosed in 1.3% [1.31–1.38] of 406,792 COVID-19 hospitalizations. SARS-CoV-2 infection was present in 2.9% ([2.82–2.97], 5,656/195,539) of all stroke hospitalizations. Discussion There was a global decline and shift to lower-volume centers of stroke admission volumes, ICH volumes, and IVT volumes during the 1st year of the COVID-19 pandemic compared with the prior year. Mechanical thrombectomy volumes were preserved. These results suggest preservation in the stroke care of higher severity of disease through the first pandemic year. Trial Registration Information This study is registered under NCT04934020.
- 24 January 2023
- Published by Wolters Kluwer Health in Neurology
- Vol. 100 (4) , e408-e421
Global Impact of the COVID-19 Pandemic on Stroke Volumes and Cerebrovascular Events
Background and Objectives Declines in stroke admission, IV thrombolysis (IVT), and mechanical thrombectomy volumes were reported during the first wave of the COVID-19 pandemic. There is a paucity of data on the longer-term effect of the pandemic on stroke volumes over the course of a year and through the second wave of the pandemic. We sought to measure the effect of the COVID-19 pandemic on the volumes of stroke admissions, intracranial hemorrhage (ICH), IVT, and mechanical thrombectomy over a 1-year period at the onset of the pandemic (March 1, 2020, to February 28, 2021) compared with the immediately preceding year (March 1, 2019, to February 29, 2020). Methods We conducted a longitudinal retrospective study across 6 continents, 56 countries, and 275 stroke centers. We collected volume data for COVID-19 admissions and 4 stroke metrics: ischemic stroke admissions, ICH admissions, IVT treatments, and mechanical thrombectomy procedures. Diagnoses were identified by their ICD-10 codes or classifications in stroke databases. Results There were 148,895 stroke admissions in the 1 year immediately before compared with 138,453 admissions during the 1-year pandemic, representing a 7% decline (95% CI [95% CI 7.1–6.9]; p < 0.0001). ICH volumes declined from 29,585 to 28,156 (4.8% [5.1–4.6]; p < 0.0001) and IVT volume from 24,584 to 23,077 (6.1% [6.4–5.8]; p < 0.0001). Larger declines were observed at high-volume compared with low-volume centers (all p < 0.0001). There was no significant change in mechanical thrombectomy volumes (0.7% [0.6–0.9]; p = 0.49). Stroke was diagnosed in 1.3% [1.31–1.38] of 406,792 COVID-19 hospitalizations. SARS-CoV-2 infection was present in 2.9% ([2.82–2.97], 5,656/195,539) of all stroke hospitalizations. Discussion There was a global decline and shift to lower-volume centers of stroke admission volumes, ICH volumes, and IVT volumes during the 1st year of the COVID-19 pandemic compared with the prior year. Mechanical thrombectomy volumes were preserved. These results suggest preservation in the stroke care of higher severity of disease through the first pandemic year. Trial Registration Information This study is registered under NCT04934020.
- Open Access
- 4 November 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (11) , 2687
CD8 Encephalitis: A Diagnostic Dilemma
CD8+ encephalitis is a subacute encephalopathy associated with HIV infection. Pathophysiology is thought to be auto-reactive CD8+ cells attacking on HIV infected CD4+ cells and ‘viral escape’ phenomena (replication of CD8+ cells in CSF). We present a case of a 45-year-old man with well controlled HIV who developed CD8 encephalitis following Herpes simplex encephalitis. He had persistent encephalopathy for several weeks with status epilepticus and agitated delirium, and diagnosis remained elusive until a brain biopsy confirmed the diagnosis.
- 4 November 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (11) , 2687
Open AccessCD8 Encephalitis: A Diagnostic Dilemma
CD8+ encephalitis is a subacute encephalopathy associated with HIV infection. Pathophysiology is thought to be auto-reactive CD8+ cells attacking on HIV infected CD4+ cells and ‘viral escape’ phenomena (replication of CD8+ cells in CSF). We present a case of a 45-year-old man with well controlled HIV who developed CD8 encephalitis following Herpes simplex encephalitis. He had persistent encephalopathy for several weeks with status epilepticus and agitated delirium, and diagnosis remained elusive until a brain biopsy confirmed the diagnosis.
- Open Access
- 7 April 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (4) , 924
Spectrum of Hemorrhagic Encephalitis in COVID-19 Patients: A Case Series and Review
Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) is an ongoing pandemic that has affected over 400 million people worldwide and caused nearly 6 million deaths. Hemorrhagic encephalitis is an uncommon but serious complication of COVID-19. The etiology of this disease is multifactorial, including secondary to severe hypoxemia, systemic inflammation, direct viral invasion, hypercoagulability, etc. The clinical spectrum of COVID-19-related hemorrhagic encephalitis is also varied, ranging from leukoencephalopathy with microhemorrhage, acute necrotizing hemorrhagic encephalitis (ANHE) involving the cortex, basal ganglia, rarely brain stem and cervical spine, hemorrhagic posterior reversible encephalopathy syndrome (PRES) to superimposed co-infection with other organisms. We report a case series of three young patients with different presentations of hemorrhagic encephalitis after COVID-19 infection and a review of the literature. One patient had self-limiting ANHE in the setting of mild COVID-19 systemic illness. The second patient had self-limiting leukoencephalopathy with microhemorrhages in the setting of severe systemic diseases and ARDS, and clinically improved with the resolution of systemic illness. Both patients were healthy and did not have any premorbid conditions. The third patient with poorly controlled diabetes and hypertension had severe systemic illness with neurological involvement including multiple ischemic strokes, basal meningitis, hemorrhagic encephalitis with pathological evidence of cerebral mucormycosis, and Epstein–Barr virus coinfection, and improved after antifungal therapy.
- 7 April 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (4) , 924
Open AccessSpectrum of Hemorrhagic Encephalitis in COVID-19 Patients: A Case Series and Review
Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) is an ongoing pandemic that has affected over 400 million people worldwide and caused nearly 6 million deaths. Hemorrhagic encephalitis is an uncommon but serious complication of COVID-19. The etiology of this disease is multifactorial, including secondary to severe hypoxemia, systemic inflammation, direct viral invasion, hypercoagulability, etc. The clinical spectrum of COVID-19-related hemorrhagic encephalitis is also varied, ranging from leukoencephalopathy with microhemorrhage, acute necrotizing hemorrhagic encephalitis (ANHE) involving the cortex, basal ganglia, rarely brain stem and cervical spine, hemorrhagic posterior reversible encephalopathy syndrome (PRES) to superimposed co-infection with other organisms. We report a case series of three young patients with different presentations of hemorrhagic encephalitis after COVID-19 infection and a review of the literature. One patient had self-limiting ANHE in the setting of mild COVID-19 systemic illness. The second patient had self-limiting leukoencephalopathy with microhemorrhages in the setting of severe systemic diseases and ARDS, and clinically improved with the resolution of systemic illness. Both patients were healthy and did not have any premorbid conditions. The third patient with poorly controlled diabetes and hypertension had severe systemic illness with neurological involvement including multiple ischemic strokes, basal meningitis, hemorrhagic encephalitis with pathological evidence of cerebral mucormycosis, and Epstein–Barr virus coinfection, and improved after antifungal therapy.
- Open Access
- 22 March 2022
- Published by MDPI AG in Healthcare
- Vol. 10 (4) , 599
Predictors of No-Show in Neurology Clinics
In this study, we aim to identify predictors of a no-show in neurology clinics at our institution. We conducted a retrospective review of neurology clinics from July 2013 through September 2018. We compared odds ratio of patients who missed appointments (no-show) to those who were present at appointments (show) in terms of age, lead-time, subspecialty, race, gender, quarter of the year, insurance type, and distance from hospital. There were 60,012 (84%) show and 11,166 (16%) no-show patients. With each day increase in lead time, odds of no-show increased by a factor of 1.0019 (p < 0.0001). Odds of no-show were higher in younger (p ≤ 0.0001, OR = 0.49) compared to older (age ≥ 60) patients and in women (p < 0.001, OR = 1.1352) compared to men. They were higher in Black/African American (p < 0.0001, OR = 1.4712) and lower in Asian (p = 0.03, OR = 0.6871) and American Indian/Alaskan Native (p = 0.055, OR = 0.6318) as compared to White/Caucasian. Patients with Medicare (p < 0.0001, OR = 1.5127) and Medicaid (p < 0.0001, OR = 1.3354) had higher odds of no-show compared to other insurance. Young age, female, Black/African American, long lead time to clinic appointments, Medicaid/Medicare insurance, and certain subspecialties (resident and stroke clinics) are associated with high odds of no show. Possible suggested interventions include better communication and flexible appointments for the high-risk groups as well as utilizing telemedicine.
- 22 March 2022
- Published by MDPI AG in Healthcare
- Vol. 10 (4) , 599
Open AccessPredictors of No-Show in Neurology Clinics
In this study, we aim to identify predictors of a no-show in neurology clinics at our institution. We conducted a retrospective review of neurology clinics from July 2013 through September 2018. We compared odds ratio of patients who missed appointments (no-show) to those who were present at appointments (show) in terms of age, lead-time, subspecialty, race, gender, quarter of the year, insurance type, and distance from hospital. There were 60,012 (84%) show and 11,166 (16%) no-show patients. With each day increase in lead time, odds of no-show increased by a factor of 1.0019 (p < 0.0001). Odds of no-show were higher in younger (p ≤ 0.0001, OR = 0.49) compared to older (age ≥ 60) patients and in women (p < 0.001, OR = 1.1352) compared to men. They were higher in Black/African American (p < 0.0001, OR = 1.4712) and lower in Asian (p = 0.03, OR = 0.6871) and American Indian/Alaskan Native (p = 0.055, OR = 0.6318) as compared to White/Caucasian. Patients with Medicare (p < 0.0001, OR = 1.5127) and Medicaid (p < 0.0001, OR = 1.3354) had higher odds of no-show compared to other insurance. Young age, female, Black/African American, long lead time to clinic appointments, Medicaid/Medicare insurance, and certain subspecialties (resident and stroke clinics) are associated with high odds of no show. Possible suggested interventions include better communication and flexible appointments for the high-risk groups as well as utilizing telemedicine.
- Open Access
- 6 September 2021
- Published by Springer Nature in Cureus
- Vol. 13 (9)
Trends in Demographics of Neurology House Staff in the United States
Background The lack of an adequate number of neurologists is a worldwide problem. As populations age, the prevalence of neurological disorders will likely increase, thereby increasing the demand for neurologists. In addition to the growing demand, inadequate diversity in the neurology healthcare workforce still exists. The purpose of this study is to examine the demographic characteristics of neurology residents and fellows. Methodology This cross-sectional study used data from the following publicly available databases: Accreditation Council for Graduate Medical Education, Association of American Medical Colleges, and the United States Census Bureau. Trends (from 2007 to 2018) in demographic characteristics were assessed using the slope and the associated p-value of a simple linear regression model, with the year as the independent variable. All p-values of <0.05 were considered significant. Results From 2007 through 2018, the percentage of US medical school graduates in neurology residency decreased from 58% to 55% (slope = -0.25; p = 0.0004), while the percentage of international medical graduates (IMGs) decreased from 36% to 32% (slope = -0.29; p = 0.0141) and doctor of osteopathy (DO) graduates increased from 6% to 13% (slope = 0.58; p < 0.0001). Although the percentage of female neurology residents increased from 39.5% in 2007 to 43.1% in 2018 (slope = 0.03; p = 0.8659), female physicians were underrepresented in vascular neurology fellowship (34% in 2018). Collectively, the percentage of underrepresented minorities in neurology residencies was low and increased only slightly over time (from 8% in 2011 to 9% in 2018; slope = 0.17; p = 0.0788). In 2018, the proportion of underrepresented minorities was smaller in neurology fellowships (5.5% neurophysiology, 12.5% epilepsy, 10.4% neuromuscular, and 12.4% vascular) compared to the population as a whole (31.3%). Conclusions IMGs still play an important role in filling a significant portion of the neurology residencies and fellowships. DO graduates have slowly increased in neurology residencies and fellowships. Members of several racial/ethnic minority groups and women are underrepresented in neurology house staff and efforts need to be taken to increase diversity.
- 6 September 2021
- Published by Springer Nature in Cureus
- Vol. 13 (9)
Open AccessTrends in Demographics of Neurology House Staff in the United States
Background The lack of an adequate number of neurologists is a worldwide problem. As populations age, the prevalence of neurological disorders will likely increase, thereby increasing the demand for neurologists. In addition to the growing demand, inadequate diversity in the neurology healthcare workforce still exists. The purpose of this study is to examine the demographic characteristics of neurology residents and fellows. Methodology This cross-sectional study used data from the following publicly available databases: Accreditation Council for Graduate Medical Education, Association of American Medical Colleges, and the United States Census Bureau. Trends (from 2007 to 2018) in demographic characteristics were assessed using the slope and the associated p-value of a simple linear regression model, with the year as the independent variable. All p-values of <0.05 were considered significant. Results From 2007 through 2018, the percentage of US medical school graduates in neurology residency decreased from 58% to 55% (slope = -0.25; p = 0.0004), while the percentage of international medical graduates (IMGs) decreased from 36% to 32% (slope = -0.29; p = 0.0141) and doctor of osteopathy (DO) graduates increased from 6% to 13% (slope = 0.58; p < 0.0001). Although the percentage of female neurology residents increased from 39.5% in 2007 to 43.1% in 2018 (slope = 0.03; p = 0.8659), female physicians were underrepresented in vascular neurology fellowship (34% in 2018). Collectively, the percentage of underrepresented minorities in neurology residencies was low and increased only slightly over time (from 8% in 2011 to 9% in 2018; slope = 0.17; p = 0.0788). In 2018, the proportion of underrepresented minorities was smaller in neurology fellowships (5.5% neurophysiology, 12.5% epilepsy, 10.4% neuromuscular, and 12.4% vascular) compared to the population as a whole (31.3%). Conclusions IMGs still play an important role in filling a significant portion of the neurology residencies and fellowships. DO graduates have slowly increased in neurology residencies and fellowships. Members of several racial/ethnic minority groups and women are underrepresented in neurology house staff and efforts need to be taken to increase diversity.
- Top Cited Papers
- 8 June 2021
- Published by Wolters Kluwer Health in Neurology
- Vol. 96 (23) , e2824-e2838
Global Impact of COVID-19 on Stroke Care and IV Thrombolysis
Objective To measure the global impact of COVID-19 pandemic on volumes of IV thrombolysis (IVT), IVT transfers, and stroke hospitalizations over 4 months at the height of the pandemic (March 1 to June 30, 2020) compared with 2 control 4-month periods. Methods We conducted a cross-sectional, observational, retrospective study across 6 continents, 70 countries, and 457 stroke centers. Diagnoses were identified by their ICD-10 codes or classifications in stroke databases. Results There were 91,373 stroke admissions in the 4 months immediately before compared to 80,894 admissions during the pandemic months, representing an 11.5% (95% confidence interval [CI] −11.7 to −11.3, p < 0.0001) decline. There were 13,334 IVT therapies in the 4 months preceding compared to 11,570 procedures during the pandemic, representing a 13.2% (95% CI −13.8 to −12.7, p < 0.0001) drop. Interfacility IVT transfers decreased from 1,337 to 1,178, or an 11.9% decrease (95% CI −13.7 to −10.3, p = 0.001). Recovery of stroke hospitalization volume (9.5%, 95% CI 9.2–9.8, p < 0.0001) was noted over the 2 later (May, June) vs the 2 earlier (March, April) pandemic months. There was a 1.48% stroke rate across 119,967 COVID-19 hospitalizations. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was noted in 3.3% (1,722/52,026) of all stroke admissions. Conclusions The COVID-19 pandemic was associated with a global decline in the volume of stroke hospitalizations, IVT, and interfacility IVT transfers. Primary stroke centers and centers with higher COVID-19 inpatient volumes experienced steeper declines. Recovery of stroke hospitalization was noted in the later pandemic months.
- 8 June 2021
- Published by Wolters Kluwer Health in Neurology
- Vol. 96 (23) , e2824-e2838
Top Cited PapersGlobal Impact of COVID-19 on Stroke Care and IV Thrombolysis
Objective To measure the global impact of COVID-19 pandemic on volumes of IV thrombolysis (IVT), IVT transfers, and stroke hospitalizations over 4 months at the height of the pandemic (March 1 to June 30, 2020) compared with 2 control 4-month periods. Methods We conducted a cross-sectional, observational, retrospective study across 6 continents, 70 countries, and 457 stroke centers. Diagnoses were identified by their ICD-10 codes or classifications in stroke databases. Results There were 91,373 stroke admissions in the 4 months immediately before compared to 80,894 admissions during the pandemic months, representing an 11.5% (95% confidence interval [CI] −11.7 to −11.3, p < 0.0001) decline. There were 13,334 IVT therapies in the 4 months preceding compared to 11,570 procedures during the pandemic, representing a 13.2% (95% CI −13.8 to −12.7, p < 0.0001) drop. Interfacility IVT transfers decreased from 1,337 to 1,178, or an 11.9% decrease (95% CI −13.7 to −10.3, p = 0.001). Recovery of stroke hospitalization volume (9.5%, 95% CI 9.2–9.8, p < 0.0001) was noted over the 2 later (May, June) vs the 2 earlier (March, April) pandemic months. There was a 1.48% stroke rate across 119,967 COVID-19 hospitalizations. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was noted in 3.3% (1,722/52,026) of all stroke admissions. Conclusions The COVID-19 pandemic was associated with a global decline in the volume of stroke hospitalizations, IVT, and interfacility IVT transfers. Primary stroke centers and centers with higher COVID-19 inpatient volumes experienced steeper declines. Recovery of stroke hospitalization was noted in the later pandemic months.
- Open Access
- 20 May 2021
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 15, 100274
Continued Underutilization of stroke care during the COVID-19 pandemic
- 20 May 2021
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 15, 100274
Open AccessContinued Underutilization of stroke care during the COVID-19 pandemic
- Open Access
- 24 March 2021
- Published by IntechOpen
Telestroke: A New Paradigm
Stroke is one of the leading causes of death and disability across the world. With the development of new modalities of treatment, including the use of intravenous tissue plasminogen activator and mechanical thrombectomy, clinical outcomes have improved in patients with acute ischemic strokes. However, these interventions are time dependent, and there exists a great disparity between the rural and urban parts of the world in terms of the availability of neurologists and these lifesaving treatment options. Telestroke networks utilize digital technology for two-way, high-resolution video teleconferencing to help abate these disparities by bringing safe, efficient, and cost-effective care to underserved communities in the United States and around the world.
- 24 March 2021
- Published by IntechOpen
Open AccessTelestroke: A New Paradigm
Stroke is one of the leading causes of death and disability across the world. With the development of new modalities of treatment, including the use of intravenous tissue plasminogen activator and mechanical thrombectomy, clinical outcomes have improved in patients with acute ischemic strokes. However, these interventions are time dependent, and there exists a great disparity between the rural and urban parts of the world in terms of the availability of neurologists and these lifesaving treatment options. Telestroke networks utilize digital technology for two-way, high-resolution video teleconferencing to help abate these disparities by bringing safe, efficient, and cost-effective care to underserved communities in the United States and around the world.